Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dyne Therapeutics issues stock options and RSUs as employment inducement awards to 14 new hires under its 2024 Inducement Stock Incentive Plan.

Rhea-AI Summary

Dyne Therapeutics (DYN) granted inducement equity awards to 14 newly hired employees under Nasdaq Listing Rule 5635(c)(4).

The awards include non-statutory stock options to purchase up to an aggregate of 278,100 shares of common stock at an exercise price equal to the closing price on Nasdaq Global Select Market on September 15, 2026, and restricted stock units covering an aggregate of 88,400 shares.

The stock options have a ten-year term and are scheduled to vest over four years, with 25% vesting on the first anniversary of each employee’s start date and the remainder vesting in 12 equal quarterly installments, subject to continued service. The restricted stock units vest over four years in four equal annual installments, also subject to continued service, under Dyne’s 2024 Inducement Stock Incentive Plan and related award agreements.

Market Context

On Aug 20, 2026, a comparable inducement-grant notice was followed by a 0.46% 24-hour move; that not...

Analysis

On Aug 20, 2026, a comparable inducement-grant notice was followed by a 0.46% 24-hour move; that notice listed 11 hires, 161,300 option shares and 51,200 RSUs versus 14 hires, 278,100 options and 88,400 RSUs here.

Key Figures

New hires receiving awards: 14 employees Stock options: 278,100 shares Restricted stock units: 88,400 shares +4 more

New hires receiving awards

14 employees

Inducement equity awards

Stock options

278,100 shares

Non-statutory options

Restricted stock units

88,400 shares

Inducement equity awards

Option term

10 years

Stock options

Option vesting period

4 years

25% on the first anniversary and remainder in 12 quarterly installments

RSU vesting period

4 years

Four equal annual installments

Initial option vesting

25%

Original shares vesting on the first anniversary

Historical Context

1 past event · Latest: Aug 20

1 event

1. Aug 20

   Inducement grants

   24h Move

   +0.5%

   Comparable grants to 11 new hires included options and restricted stock units.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), non-statutory stock options, restricted stock units

3 terms

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

non-statutory stock options financial

"The inducement equity awards consisted of non-statutory stock options"

Non-statutory stock options are a type of reward that companies give to employees, allowing them to buy company shares at a set price within a certain period. Unlike formal or government-approved plans, these options are more flexible but may have different tax implications. For investors, they can influence a company's stock price and financial health, making them an important factor to consider.

restricted stock units financial

"and restricted stock units with respect to an aggregate"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WALTHAM, Mass., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 14 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement equity awards consisted of non-statutory stock options to purchase up to an aggregate of 278,100 shares of Dyne’s common stock at a per share exercise price equal to the closing price of Dyne’s common stock on The Nasdaq Global Select Market on September 15, 2026, and restricted stock units with respect to an aggregate of 88,400 shares of Dyne’s common stock. The stock options have a ten-year term and are scheduled to vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s start date and the remainder vesting in 12 equal quarterly installments thereafter, subject to such employee’s continued service to Dyne through the applicable vesting dates. The restricted stock units are scheduled to vest over four years from the applicable employee’s start date in four equal annual installments, subject to such employee’s continued service to Dyne through the applicable vesting dates.

The inducement equity awards are subject to the terms and conditions of award agreements covering the grants and Dyne’s 2024 Inducement Stock Incentive Plan.

About Dyne Therapeutics

Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/, and follow us on X, LinkedIn and Facebook.

Contacts:
Investors
Mia Tobias
ir@dyne-tx.com
781-317-0353

Media
Stacy Nartker
snartker@dyne-tx.com
781-317-1938